[A case of metastatic choriocarcinoma responding to combination chemotherapy with paclitaxel and carboplatin].

Abstract

A 53-year-old woman with choriocarcinoma (high-risk gestational trophoblastic disease: FIGO score 17) was treated with paclitaxel (175 mg/m(2)) and carboplatin (AUC=5). The patient was treated with an EMA/CO regimen as initial chemotherapy, but she developed EMA/CO-induced interstitial lung disease after the 3rd course of treatment. After high-dose steroid therapy, she received combination chemotherapy with paclitaxel and carboplatin. Her hCG-/b dropped to <0.1 ng/mL after 11 courses of the chemotherapy. A paclitaxel+carboplatin regimen is potentially effective for high-risk GTD, but a more effective combination or schedule with a platinum-taxane regimen should be explored.

• Authors: Kumi Shimamoto, Shigeru Inatomi, Hidenori Fujimoto, Hisao Sumioki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 37 Issue 5 Pg. 943-6 (May 2010) ISSN: 0385-0684 [Print] Japan
• PMID: 20495335 (Publication Type: Case Reports, Journal Article)

Chemical References

• Chorionic Gonadotropin, beta Subunit, Human
• Carboplatin
• Paclitaxel

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage, therapeutic use)
• Choriocarcinoma (blood, diagnostic imaging, drug therapy, pathology)
• Chorionic Gonadotropin, beta Subunit, Human (blood)
• Female
• Humans
• Lung Neoplasms (blood, diagnostic imaging, drug therapy, secondary)
• Middle Aged
• Paclitaxel (administration & dosage, therapeutic use)
• Pregnancy
• Remission Induction
• Tomography, X-Ray Computed
• Uterine Neoplasms (blood, diagnostic imaging, drug therapy, pathology)